Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 20;238(10):2693–2708. doi: 10.1007/s00213-021-05954-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Effect of daily, repeated administrations of almorexant and zolpidem on sleep promotion in rats. Male Wistar rats received daily repeated oral administrations of almorexant (100 mg/kg p.o.) or vehicle at the beginning of the night (arrows), active period (gray rectangles) for 6 weeks, followed by 7 days of recovery. Sleep was recorded via EEG/EMG-based telemetry. Data were averaged across several days per week, except for the first recovery night and day; 2 days/nights for week 0, and 4 days/nights for each of weeks 1–6. Repeated administration was also performed with zolpidem (30 mg/kg p.o.) for 5 consecutive days, followed by 1 day of recovery. Almorexant data are represented as the mean ± standard error of the mean of eight rats per group. Zolpidem data are presented as the mean ± standard error of the mean of seven rats per group. Two-way ANOVA followed by post hoc Bonferroni test: *p < 0.05, **p < 0.01, ***p < 0.001, vs. the vehicle-treated group. REM, rapid eye movement; EEG, electroencephalography; EMG, electromyography. Data-on-file (see Online Resource S3 for experimental details)